

## Commercial/Healthcare Exchange PA Criteria

Effective: May 1, 2018

**Prior Authorization:** Bowel Preparations

**Products Affected:** Prepopik, Clenpiq, Plenvu, Suflave

**Medication Description:** Clenpiq (sodium picosulfate, magnesium oxide, and anhydrous citric acid) oral solution is a stimulant and osmotic laxative that is provided as a cranberry-flavored, colorless to slightly yellow, clear oral solution, and is supplied as two bottles in each carton. Each bottle of Clenpiq contains 10 mg sodium picosulfate, USP; 3.5 g magnesium oxide, USP; and 12 g anhydrous citric acid, USP. The product also contains the following inactive ingredients: acesulfame potassium, cranberry flavor, disodium edetate, malic acid, sodium benzoate, sodium hydroxide, sodium metabisulfite, sucralose, and water. The cranberry flavor contains glyceryl triacetate (triacetin), maltodextrin and sodium octenyl succinated starch.

**Covered Uses:** Cleansing of the colon as a preparation for colonoscopy.

**Exclusion Criteria:**

1. Patients with severely reduced renal function (creatinine clearance less than 30 mL/minute) **[Clenpiq/Prepopik]**
2. Bowel perforation
3. Gastric retention
4. Gastrointestinal obstruction or ileus
5. Toxic colitis or toxic megacolon

**Required Medical Information:**

1. Previous therapy tried/failed
2. Chart notes documenting treatment failure or allergy

**Age Restrictions:**

Clenpiq, Prepopik: 9 years of age and older

Plenvu, Suflave: 18 years of age and older

**Prescriber Restrictions:** Prescribed by or in consultation with a gastroenterologist.

**Coverage Duration:** 12 months

**Other Criteria:**

- A. Member has history of failure of Suprep **OR** MoviPrep defined as:
  - a. Failure to complete cleansing of the colon as a preparation for colonoscopy; **OR**
- B. Member has intolerance to Suprep **OR** MoviPrep, defined as (but not limited to):
  - a. Allergic reaction; **OR**
  - b. Adverse drug reactions

**References:**

1. Clenpiq [package insert]. Parsippany, NJ; Ferring Pharmaceuticals; October 2019.
2. Prepopik [package insert]. Parsippany, NJ; Ferring Pharmaceuticals; August 2018.
3. “Task Force Releases Updated Recommendations for Colorectal Cancer Screening.” American Gastroenterological Association. June 22, 2017. [www.gastro.org/news\\_items/task-force-releases-updated-recommendations-for-colorectal-cancer-screening](http://www.gastro.org/news_items/task-force-releases-updated-recommendations-for-colorectal-cancer-screening). Accessed February 28, 2018.
4. “Colonoscopy.” National Institute of Diabetes and Digestive and Kidney Diseases. U.S. Department of Health and Human Services. July 2017. [www.niddk.nih.gov/health-information/diagnostic-tests/colonoscopy](http://www.niddk.nih.gov/health-information/diagnostic-tests/colonoscopy). Accessed February 28, 2018.
5. PLENVU® powder for oral solution, polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride, potassium chloride powder for oral solution. Salix Pharmaceuticals Ltd (per FDA), Bridgewater, NJ, May 2019.
6. Product Information: SUFLAVE® oral solution, polyethylene glycol 3350 sodium sulfate potassium chloride magnesium sulfate sodium chloride oral solution. Braintree Laboratories, Inc (per FDA), Holbrook, MA, 2023.

**Policy Revision history**

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	04/17/2018
2	Update	Addition of new drug: Plenvu	Products Affected	08/28/2018
3	Update	Age Restriction for Prepopik	Age Restriction	5/2019
4	Update	Updates per FDA label	Exclusion Criteria Age Restrictions	01/14/2020
5	Update	Added Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Solution	Products Affected, Age Restrictions	8/22/2022
6	Update	Removed Sodium Sulfate, Potassium Sulfate and Magnesium Sulfate Solution from Products Affected and Age restrictions	Products Affected, Age Restrictions	9/28/2022
7	Update	Added Sulflave	Products Affected, Age Restriction	10/24/2023